Therox, the maker of a device that could quickly salvage damaged heart tissue after a heart attack, is in the midst of a sizable equity round – its largest since it a failed IPO attempt during the recession and a snub from the FDA.
Therox just raised $16.8 million of a proposed $23.1 million equity round, according to a regulatory filing. The privately held Irvine, Calif. devicemaker is using this round to recapitalize and move into a final round of clinical trials that’ll have 100 participants, Dow Jones reports.
Help employers find you! Check out all the jobs and post your resume.
Therox just raised $16.8 million of a proposed $23.1 million equity round, according to a regulatory filing. The privately held Irvine, Calif. devicemaker is using this round to recapitalize and move into a final round of clinical trials that’ll have 100 participants, Dow Jones reports.
Help employers find you! Check out all the jobs and post your resume.
